Search

Objective. To analyze the pathway of clinical trials of monoclonal antibodies and biological medicines for cancer treatment involving Brazilian institutions from 2003 to 2012. Method. This retrospective, descriptive study was based on review of two clinical trial registries, ClinicalTrials.gov and the Brazilian registry ReBEC. Phase II or III studies with participation from Brazilian institutions listed in at least one of the registries were included. Following selection of the trials, the pathway of monoclonal antibodies and biological medicines was investigated from the research stage until licensing by the Brazilian Agency for Sanitary Surveillance (Anvisa), Food and Drug Administration (FDA), and European Medicines Agency (EMA). Results. Nine trials (eight phase III and one phase II) were selected. All had a randomized, controlled design. Two trials were double-blind and seven were open-label, and all recruited adults (> 18 years of age) of both sexes. The mean number of patients recruited per trial was 985.2. Seven trials had been completed and two had been terminated early. All trials were sponsored by non-Brazilian pharmaceutical companies and focused on renal, colorectal, gastric, and lung (non-small cell) cancer, non-Hodgkin lymphoma, and melanoma, and involved the use of cetuximab, figitumumab, ipilimumab, rituximab, bevacizumab and interferon alfa-2a. The FDA was the first agency to license the drugs, followed by EMA, except in the case of interferon alfa-2a, which was not approved by EMA. We were unable to determine the year of drug licensing by Anvisa in Brazil. Conclusions. The participation of Brazil in clinical trials of monoclonal antibodies and biological medications for cancer treatment is insufficient. The quality of the available information on trials, history of licensing, and other relevant elements is a major weakness of the sources reviewed. [ABSTRACT FROM AUTHOR]

Realizing the Potential of Monoclonal Antibodies. Muradel, Algarythm, SARDI and many more lead premier line-up at CMT's 3rd Algae World Australia. [ABSTRACT FROM AUTHOR]

The Biotechnology Incubation Center of Academia Sinica: A Gateway to Innovative Taiwan. Cancer Targeting Nanomedicine: An Opportunity for Drug Development in Asia with Emphasis on Taiwan. Recombinant Lipoproteins for the Development of Novel Subunit Vaccines. Discovery of Therapeutic Human Monoclonal Antibodies through B-cell Immortalization Technology. [ABSTRACT FROM AUTHOR]

Trump was given an 8 gram dose of Regeneron's monoclonal antibody treatment following a "compassionate use" request from his doctors. [ABSTRACT FROM AUTHOR]

Two monoclonal antibody preparations have been demonstrated to significantly reduce mortality in patients with Ebola virus infection. [ABSTRACT FROM AUTHOR]